Skip to main content

Table 3 Patient characteristics and outcomes at discharge a

From: Procalcitonin guidance for reduction of antibiotic use in patients hospitalized with severe acute exacerbations of asthma: a randomized controlled study with 12-month follow-up

 

PCT group (n = 90)

Control group (n = 90)

P-value

Antibiotic use, n (%)

44 (48.9)

79 (87.8)

<0.001

Clinical success, n (%)

90 (100)

90 (100)

1.00

Duration of antibiotic, days

6 (4 to 9)

6 (3 to 8)

0.198

Length of hospital stay, days

9 (6 to 11)

8 (6 to 12)

0.380

Need for intubation, n (%)

14 (15.5)

11 (12.2)

0.518

FEV1,% of predicted value

   

Prebronchodilator

70.9 ± 12.8

72.4 ± 11.2

0.404

Postbronchodilator

75.4 ± 11.6

77.1 ± 12.5

0.345

CRP, mg/L

9.3 ± 3.4

9.7 ± 4.2

0.509

WBC, ×109/L

7.1 ± 2.1

7.4 ± 1.9

0.469

PCT, μg/L

0.041 (0.028 to 0.063)

0.046 (0.032 to 0.071)

0.723

  1. aCRP, C-reactive protein; FEV1, Forced expiratory volume in 1 second; PCT, procalcitonin; WBC, white blood cells. Data are presented as number (%), median (IQR) or mean ± SD.